Patents by Inventor Yen-Fang Wen

Yen-Fang Wen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION FOR INHIBITING INTESTINAL PERMEABILITY, TREATING LEAKY GUT RELATED DISEASES AND/OR PREVENTING LEAKY GUT RELATED DISEASES
    Publication number: 20240165181
    Abstract: A composition for inhibiting intestinal permeability, treating leaky gut related diseases and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes Ganoderma, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes a Ganoderma extract, a red jujube extract, a longan extract and a lotus seed extract.
    Type: Application
    Filed: June 1, 2023
    Publication date: May 23, 2024
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: I-Hong PAN, Kuei-Chang LI, Zong-Keng KUO, Chu-Hsun LU, Yen-Wu HSIEH, Shu-Fang WEN
  • Monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)-piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, preparation, and pharmaceutical composition thereof
    Patent number: 9012459
    Abstract: The disclosure is directed to a monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, possessing diffraction peaks of about 12.9°, 15.9°, 17.9°, 21.2°, 22.9°, 23.5° and 24.5°. Its preparation method and pharmaceutical composition thereof are also provided.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: April 21, 2015
    Assignee: Industrial Technology Research Institute
    Inventors: Yen-Fang Wen, Yuan-Jang Tsai, Wan-Ru Chen, Tsan-Lin Hu, Chia-Mu Tu, Chih-Peng Liu
  • Monohydrate Crystalline Form of 3-(5-(4-(3-Fluoropropyl)-Piperazin-1-YL)Benzimidazol-2-YL)-1-Azaazulen-2-One, Preparation, and Pharmaceutical Composition Thereof
    Publication number: 20140171443
    Abstract: The disclosure is directed to a monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, possessing diffraction peaks of about 12.9°, 15.9°, 17.9°, 21.2°, 22.9°, 23.5° and 24.5°. Its preparation method and pharmaceutical composition thereof are also provided.
    Type: Application
    Filed: August 15, 2013
    Publication date: June 19, 2014
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Yen-Fang WEN, Yuan-Jang TSAI, Wan-Ru CHEN, Tsan-Lin HU, Chia-Mu TU, Chih-Peng LIU
  • Hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
    Patent number: 7332615
    Abstract: The present invention discloses hydrophilic derivatives of 4,8-dihydrobenzodithiophene-4,8-diones, which are active as anticancer agents, along with pharmaceutical formulations containing the same.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: February 19, 2008
    Assignees: Industrial Technology Research Institute, Yung Shin Pharm. Ind. Co., Ltd.
    Inventors: Pi-Tsan Huang, Yen-Fang Wen, Wuu-Chian Shin, Mei-Hwai Chen, Sheng-Chu Kuo, Kuo-Hsiung Lee
  • Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
    Publication number: 20060069041
    Abstract: The present invention discloses hydrophilic derivatives of 4,8-dihydrobenzodithiophene-4,8-diones, which are active as anticancer agents, along with pharmaceutical formulations containing the same.
    Type: Application
    Filed: September 28, 2005
    Publication date: March 30, 2006
    Applicants: Industrial Technology Research Institute, YUNG SHIN PHARM. IND. CO., LTD.
    Inventors: Pi-Tsan Huang, Yen-Fang Wen, Wuu-Chian Shin, Mei-Hwai Chen, Sheng-Chu Kuo, Kuo-Hsiung Lee